Development of therapeutics for AIDS: structure-based molecular targeting.
Novel anti-HIV agents that target different stages of the human immunodeficiency virus type 1 (HIV-1) replication cycle are now in clinical trials and have signs of improving our ability to manage HIV-1. This chapter, and the Conference presentation, dealt with the challenges encountered in realizing the optimal benefits of the newer therapeutics to individuals with AIDS and HIV-1 infection receiving highly active antiretroviral therapy (HAART). Emphasis was on the G-protein-coupled seven-transmembrane chemokine receptor, CCR5, as a potentially new therapeutic target and experience with novel CCR5 inhibitors, and the promise from further advancement through structural and molecular analysis of CCR5 inhibitor-CCR5 interactions. The promise in some of the newer protease inhibitors was also discussed.
Maeda
Kenji
K
Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA. maedak@mail.nih.gov
Mitsuya
Hiroaki
H
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D065100:CCR5 Receptor Antagonists; D000069454:Darunavir; D015195:Drug Design; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D015394:Molecular Structure; D013449:Sulfonamides / Q000627:therapeutic use
D044966:Anti-Retroviral Agents; D065100:CCR5 Receptor Antagonists; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir